Welcome to our dedicated page for Healthcare Triangle SEC filings (Ticker: HCTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Healthcare Triangle, Inc. (HCTI) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered tools to help interpret complex documents. As an emerging growth company listed on The Nasdaq Stock Market LLC, Healthcare Triangle files a variety of reports that shed light on its healthcare IT and digital health operations, capital structure, and governance.
For investors analyzing HCTI, Form 10-K annual reports and Form 10-Q quarterly reports are central sources for understanding its healthcare information technology business, including cloud and data platforms (CloudEz™ and DataEz™), security and compliance services, data lifecycle management, interoperability work, and clinical and business performance optimization. These filings also describe risk factors, segment information, and accounting policies relevant to its software, managed services, and platform offerings.
Healthcare Triangle’s Form 8-K current reports are particularly important given the company’s active financing and acquisition strategy. Recent 8-Ks disclose:
- Material definitive agreements for senior unsecured convertible promissory notes under a Securities Purchase Agreement.
- Warrant inducement agreements and related new warrant issuances, including changes to exercise prices and registration commitments.
- Reverse stock split actions intended to address Nasdaq bid price requirements.
- Asset transfer and acquisition-related amendments involving Niyama Healthcare, Inc. and Ezovion Solutions Private Limited.
- Nasdaq compliance communications regarding listing rules and shareholder approval requirements.
Proxy statements on Schedule 14A detail proposals for electing directors, ratifying auditors, and obtaining shareholder approval for future securities issuances under Nasdaq Listing Rule 5635(d). These documents also explain voting rights, meeting logistics, and aspects of the company’s governance framework.
On this page, Stock Titan surfaces real-time updates from EDGAR and applies AI-powered summaries to key filings. Users can quickly see the main terms of financing agreements, the structure of warrant and note offerings, and the implications of reverse stock splits or listing determinations. Where applicable, insider ownership and voting power information disclosed in proxy materials can be reviewed alongside other filings, while Form 4 insider trading reports, when available, provide additional context on management and major holder transactions.
By combining raw SEC documents with AI-generated explanations, this filings hub helps investors, analysts, and researchers navigate Healthcare Triangle’s regulatory history and understand how its capital markets activity, acquisitions, and governance decisions support its healthcare IT and AI-driven digital health strategy.
Healthcare Triangle, Inc. entered into a warrant inducement agreement under which certain existing warrant holders agreed to exercise warrants for cash to buy up to 1,429,528 shares of common stock at $2.00 per share. The exercises, completed on October 2, 3 and 8, 2025, generated aggregate gross proceeds of approximately $2.85 million before fees and expenses, which the company expects to use for working capital and general corporate purposes.
In return, the company issued new unregistered warrants for up to 1,429,528 additional shares at an exercise price of $3.00 per share, with a five-year term and exercisability beginning after required stockholder approval. A financial advisor received a 6.0% cash fee on gross proceeds, expense reimbursement up to $20,000, advisor warrants equal to about 2.0% of the new warrant shares at $3.00 per share, and a six-month right of first refusal on future offerings. The new warrants include ownership caps of 4.99% or 9.99% and permit cashless exercise if a registration for the new warrant shares is not effective after six months.
Healthcare Triangle, Inc. is circulating a preliminary proxy statement for a virtual annual meeting that includes three explicit actions: elect four directors to serve until the 2026 annual meeting, ratify the appointment of SRCO Professional Corporation, Chartered Professional Accountants as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and transact any other properly presented business. The materials describe voting mechanics for record holders and beneficial holders, note that a quorum requires a majority of outstanding voting stock, and state there are 20,000 shares of Series A Super Voting Preferred Stock outstanding with 1,000 votes per share; the number of common shares outstanding is presented as a placeholder and not specified. The company will pay proxy-solicitation costs and reimburse brokers for forwarding materials. Healthcare Triangle discloses it is an "emerging growth company" and summarizes committee responsibilities, director names and ages (Dave Rosa, Sujatha Ramesh, Ronald McClurg, Jainal Bhuiyan). Several ownership and disclosure fields in the filing appear as placeholders or truncated.
Healthcare Triangle, Inc. announced that Nasdaq has confirmed the company has regained compliance with Listing Rule 5635(a)(1), which requires shareholder approval before issuing common stock equal to 20% or more of pre-transaction voting power in an acquisition. Nasdaq’s earlier concern came from Healthcare Triangle’s agreement to issue approximately 345,622,120 shares of common stock, which would have represented about 33.8% of its pre-transaction outstanding shares, as consideration for acquiring Niyama Healthcare, Inc. and Ezovion Solutions Private Limited, without prior shareholder approval. On August 28, 2025, the company amended the acquisition agreement so that issuing these shares, as adjusted for a prior 1-for-249 reverse stock split, is conditioned on shareholder approval, leading Nasdaq to state that no further action is required and that the company remains in compliance with all continued listing requirements. The company also furnished an Investor Presentation as Exhibit 99.1, providing updates on operations, strategy, growth initiatives and outlook.
Healthcare Triangle, Inc. filed an amended current report to update terms of its asset transfer deal with Niyama Healthcare, Inc. The amendment changes the consideration so the seller will receive 1,388,041 restricted shares of Healthcare Triangle common stock, issuable on the effective date after approval by a majority of the company’s voting power. The change reflects a previously implemented 1-for-249 reverse stock split and leaves the rest of the agreement intact.
The filing also adds audited financial statements for Niyama Healthcare, Inc. and Ezovion Solutions Private Limited for 2023 and 2024, along with unaudited pro forma condensed combined financial information showing the impact of the transaction on Healthcare Triangle’s financials.
L1 Capital Global Opportunities Master Fund, Ltd. filed an amendment to Schedule 13G reporting beneficial ownership of 1,417,420 shares of Healthcare Triangle, Inc. (HCTI), equal to 0.35% of the company's outstanding common stock based on 408,445,597 shares. The filing states this total includes 464,681 shares issued on conversion of $200,000 of a convertible promissory note, 595,239 shares underlying warrants and 357,500 shares underlying additional warrants. The report notes it does not reflect potential additional securities from anti-dilution protection and that beneficial ownership would be limited to 9.9% even if related discussions were resolved within 60 days. Directors David Feldman and Joel Arber are identified in the filing.
Healthcare Triangle, Inc. (HCTI) reported a quarter showing a completed acquisition, a large reverse stock split and continued operating losses. On June 16, 2025 the company closed an asset acquisition for $5.7 million comprised of $1.5 million cash (with $1.2 million paid at closing and $300,000 payable later), restricted common stock equal to $3.0 million issued at roughly $2.16–$2.17 per share, and up to $1.2 million of contingent earn-outs. The Company effected a 1-for-249 reverse split of common stock on August 1, 2025 and adjusted basic and diluted earnings for all periods. Cash and cash equivalents changed by +$3,208 (net increase) for the period reported. The company reported net losses reflected in negative basic and diluted EPS (examples shown: $(0.58) and $(70.72) in one presentation and $(2.56) and $(171.85) in another), high customer concentration in receivables (five customers represented ~52% and ~72% of accounts receivable), and a financing that produced net proceeds of approximately $13,676 after fees.
Healthcare Triangle, Inc. ("HCTI") filed an 8-K announcing the completed acquisition of mental-health and hospital-information-system (HIS) assets from Niyama Healthcare, Inc. and the seller’s 100 % equity stake in Ezovion Solutions Private Limited. The transaction closed on 16 June 2025 and is structured as an asset and stock purchase, with all liabilities of the seller excluded.
Purchase Price – US $5.7 million: (1) US $1.5 million cash (US $1.2 million paid at close; US $0.3 million payable within 120 days or upon satisfaction of withholding requirements); (2) approximately 345.4 million restricted HCTI shares, calculated as US $3.0 million divided by US $0.00868 per share, issued at closing; (3) up to US $1.2 million in earn-out payments tied to first-year performance metrics to be finalized within 90 days.
Assets acquired: all software IP, customer contracts, permits/licences and business records relating to the seller’s mental-health and HIS technology operations across India, South-East Asia and Europe, plus the full equity interest in Ezovion Solutions Private Limited, an HIS SaaS provider headquartered in Chennai, India.
Key contractual protections: the seller will continue operating support services (revenue collection, payroll) through 15 August 2025 and must remit all post-closing revenues to HCTI under a defined schedule. Comprehensive indemnities protect HCTI from breaches of representations, covenants, or pre-closing liabilities. A two-year non-disclosure covenant is in place.
Accounting & reporting: the acquisition is treated as a business combination. Any required financial statements and pro-forma information will be filed within 71 days by amendment. The equity issued represents a material increase to HCTI’s outstanding share count and will be unregistered, reported under Item 3.02.
Strategic rationale: the deal expands HCTI’s cloud-based healthcare portfolio into fast-growing emerging markets and adds complementary SaaS IP. Excluding liabilities and obtaining seller support lowers integration risk, while the earn-out aligns payment with post-acquisition performance.
Forward-looking statements warning and safe-harbor language were included. A related press release (Exhibit 99.1) was furnished but not deemed “filed” under the Exchange Act.